Brynovin (Sitagliptin Oral Solution)

Brynovin (sitagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use: This therapeutic drug is not recommended in patients with type 1 diabetes. It has not been studied in those with a known history of pancreatitis.

Recommended Dosage: The recommended dose of Brynovin is 100 mg (4 mL) orally once daily. Dosage can be taken with or without food. Patients with an eGFR less than 45 mL/min/1.73 m² require dosage adjustments as per medical guidance. Proper monitoring of kidney function is essential to ensure safe and effective use. Patients should follow their healthcare provider’s (HCP) instructions regarding dose modifications if necessary.
Missing doses of Brynovin should be avoided, and medicine should be taken at the same time each day for consistency. Always consult a doctor or pharmacist before making any changes to your dosage or treatment plan.

• Brynovin has the potential to cause an onset of pancreatitis, in particular, in all those who have a previous history of such diseases. Look out for signs which may include but are not limited to nausea, and vomiting, as well as pain in the abdominal area. If any indications of pancreatitis do appear, you must stop taking the medicine and contact your doctor as soon as possible.
• Patients suffering from heart failure need to be very careful while using Brynovin. It can worsen already existing conditions indicating advanced stages of heart failure including dyspnea, edema, fatigue, and many more. In these patients, there should be periodic checks for the condition of the heart.
• Brynovin can have some effects on the functionality of the kidneys which can lead to acute renal failure, as well as patients already suffering from renal failure. The medication should be taken with extreme caution. During these treatments, the renal function must be assessed and in case a significant impairment or any other changes in terms of the functionality of the kidneys are observed, the treatment must be halted.
• Many allergic reactions may occur from the intake of Brynovin oral solution, which might include a rash, inflammation, or swelling. It can also lead to a person being unable to breathe as well. Sudden death due to allergic reactions is possible, and therefore stopping the medicine may be crucial in such cases. Emergency medical help should also be taken.
• Cases of bullous pemphigoid (a rare skin blistering condition) have also been reported with the treatment of Brynovin 25 mg/mL. In case there are blisters, erosions, or rashes, patients need to inform their doctors immediately. If bullous pemphigoid is found, the oral medication should be stopped.
• This medicine can be taken during pregnancy only if its benefits are greater than its risks. There are few studies where animals have suffered from some consequences and there is not enough evidence in humans. Seek medical advice if you are pregnant or plan to be pregnant and need to use this medication.
• Use of this therapeutic drug is not recommended during breastfeeding because of its possible transfer into milk and potential effects on the infant. In case you are breastfeeding or planning to breastfeed, talk to your healthcare provider (HCP) about other treatment options.

What documents are required to import BRYNOVIN to India?

BRYNOVIN (sitagliptin) oral solution can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is BRYNOVIN available in India?

BRYNOVIN (sitagliptin oral solution) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Brynovin in India (Mumbai, Kolkata,
• Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait,
• Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

BRYNOVIN can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of BRYNOVIN (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Brynovin 25 mg/mL price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source BRYNOVIN (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Brynovin®?

Sitagliptin is a Generic Name for the trade name drug Brynovin®.

What is the Manufacturer's Name of Brynovin®?

Brynovin® is manufactured by Azurity Pharmaceuticals Inc.

Is Brynovin approved by the FDA?

Yes, Brynovin® is approved by the FDA. Date of first approval: January 16, 2025.

What is the dosage and form of Brynovin® supplied?

Brynovin is supplied for oral solution: 25 mg per mL for oral administration.

What are the most common side effects of Brynovin® 25 mg/mL oral solution?

The most common side effects of Brynovin® 25 mg/mL oral solution are upper respiratory tract infection, nasopharyngitis and headache.

How much does Brynovin® 25 mg/mL oral solution cost in India?

The price of Brynovin 25 mg/mL oral solution may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Brynovin 25 mg/mL oral solution cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Brynovin® 25 mg/mL oral solution be available in SAARC countries?

Apart from Gulf countries, Brynovin® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Brynovin® oral solution in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Brynovin® 25 mg/mL oral solution online in India?

Yes, one can buy Brynovin 25 mg/mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Brynovin® oral solution through legal channels.

What are the storage conditions of Brynovin® 25 mg/mL oral solution?

Store refrigerated at 2°C to 8°C (36°F to 46°F); Protect from light. Avoid excessive heat and freezing. Discard unused portion 90 days after first opening.